Cargando…
Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy
Autor principal: | Silverman, Stuart L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Current Science Inc.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026771/ https://www.ncbi.nlm.nih.gov/pubmed/21161452 http://dx.doi.org/10.1007/s11914-010-0044-x |
Ejemplares similares
-
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017) -
The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension
por: Ramchand, Sabashini K., et al.
Publicado: (2022) -
Combination Therapy With Zoledronic Acid and FES‐Row Training Mitigates Bone Loss in Paralyzed Legs: Results of a Randomized Comparative Clinical Trial
por: Morse, L R, et al.
Publicado: (2019) -
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
por: Garnett, Sally Anne, et al.
Publicado: (2013) -
Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects
por: Täubel, Jörg, et al.
Publicado: (2016)